Professor Zeng Zexian's team from the Center for Quantitative Biology at the Peking University Academy for Advanced Interdisciplinary Studies, in collaboration with the Peking University-Tsinghua ...

Dr. Aaron Robinson, an ear nose and throat specialist, said it can be tough to distinguish between allergies and cold or flu ...

UNM Cancer C enter professor 's study of immunotherapy funded by $2M grant ...

Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

A new article outlines a new tool that measures blood inflammation as a marker for poor CAR T therapy outcomes.

There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells ...

Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

A bold funding initiative aims to help scientists predict a T cell’s target antigens, with implications far beyond cancer ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.